Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVNFree Report) in a research note released on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their price objective on shares of Trevena from $225.00 to $125.00 and set a buy rating on the stock in a research report on Thursday, May 16th.

Check Out Our Latest Stock Report on Trevena

Trevena Trading Down 11.2 %

Trevena stock opened at $5.95 on Friday. The firm has a market cap of $5.06 million, a P/E ratio of -2.22 and a beta of 1.03. Trevena has a 1-year low of $3.35 and a 1-year high of $25.75. The firm has a 50-day moving average of $5.04 and a 200-day moving average of $8.52.

Trevena (NASDAQ:TRVNGet Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($9.25) by $9.02. The business had revenue of $0.33 million during the quarter. Research analysts forecast that Trevena will post -32.25 earnings per share for the current fiscal year.

Institutional Trading of Trevena

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC acquired a new position in Trevena, Inc. (NASDAQ:TRVNFree Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent quarter. Hedge funds and other institutional investors own 13.56% of the company’s stock.

About Trevena

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

See Also

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.